TEL AVIV, Israel and BETHESDA, Maryland, June 25, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects,...
Cannabics Pharmaceuticals Inc.
Our goal is to help treat cancer with precision
Biotechnology
1d
5d
1m
6m
1y
Max
Cannabics Pharmaceuticals Inc. News
04 Jun
Cannabics Pharmaceuticals to Participate at the LIFT & Co. Conference in Toronto, Canada
TEL AVIV, Israel and BETHESDA, Maryland, June 4, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today...
30 May
Cannabics Pharmaceuticals to Participate at the 9th Annual LD Micro Invitational in Bel Air, California
Mr. Eyal Barad (CEO of Cannabics Pharmaceuticals) will be presenting and meeting with investors. "This year's Invitational will showcase some of the most unique names in the financial world, from early-stage...
25 Apr
Cannabics Pharmaceuticals' CEO to Present at the Planet MicroCap Conference in Las Vegas and at the ThinkEq
TEL AVIV, Israel and BETHESDA, Maryland, April 25, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced...
17 Apr
Cannabics Pharmaceuticals Announces Initiation of a Nationwide Clinical Study to Evaluate Antitumor Propert
TEL AVIV, Israel and BETHESDA, Maryland, April 17, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects,...
Seedo Corp. is an agro-tech company providing the world's first fully automated and controlled indoor growing machine for pesticide-free agricultural and vertical farming markets. Cannabics owns approximately...
Companies Will Launch New Entity to Research and Develop Cannabinoid Formulations to Treat Ophthalmic Conditions HOD HASHARON, Israel , March 6 , 2019 /PRNewswire/ -- Wize Pharma, Inc. ("Wize Pharma"...
BETHESDA, Maryland and TEL AVIV, Israel, March 6, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its side effects,...
19 Feb
Cannabics Pharmaceuticals Submits Protocol for an Ex-Vivo Clinical Study on Biopsies and Cannabinoids
Cannabics has submitted a protocol for the Helsinki Committee to conduct a nationwide study on fresh biopsies treated with a multitude of cannabinoid compounds and chemotherapies TEL AVIV, Israel and BETHESDA,...
07 Feb
Cannabics Pharmaceuticals and Wize Pharma to Form Joint Venture to Develop Cannabinoid Based Ophthalmic The
BETHESDA, Maryland and TEL AVIV, Israel, Feb. 7, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its side effects,...
About Cannabics Pharmaceuticals Inc.
Cannabics Pharmaceuticals Inc. (CNBX) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient’s profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer.
Our lab is equipped with a collection of state of the art instruments to enable miniaturization and automation of a variety of biological assays. The automated system is comprised of:
High Content Screening (HCS) Platform, which is an automated cellular imaging and analysis platform designed for quantitative microscopy.
- Flow Cytometry, which enables multi-parametric single cell analysis.
- Automated workstation, for liquid handling for dispensing accurate and reproducible volumes of liquids and compounds.
- Multimode microplate reader designed for fast measurements of numerous biological reactions/processes.
Readouts generated from these instruments provide us with insights to the effect of our cannabinoid library on parameters such as, proliferation inhibition, apoptosis induction, angiogenesis and toxicity on cancerous cells.
Team
David E. Price, Esq
Secretary, Corporate Counsel
$ 0.01
-14.29%
Open:
0.01
High:
0.02
Low:
0.01
Symbol:
CNBX
Contact info
Phone:
+1-877-424-2429
+972-3-6589991
Address:
7450 Wisconsin Ave, Bethesda, MD 20814, USA
